Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


African Trypanosomiasis-Pipeline Review, H2 2016

African Trypanosomiasis-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

African Trypanosomiasis-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'African Trypanosomiasis-Pipeline Review, H2 2016', provides an overview of the African Trypanosomiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of African Trypanosomiasis

The report reviews pipeline therapeutics for African Trypanosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved African Trypanosomiasis therapeutics and enlists all their major and minor projects

The report assesses African Trypanosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for African Trypanosomiasis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for African Trypanosomiasis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding African Trypanosomiasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

African Trypanosomiasis Overview 7

Therapeutics Development 8

Pipeline Products for African Trypanosomiasis-Overview 8

Pipeline Products for African Trypanosomiasis-Comparative Analysis 9

African Trypanosomiasis-Therapeutics under Development by Companies 10

African Trypanosomiasis-Therapeutics under Investigation by Universities/Institutes 11

African Trypanosomiasis-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

African Trypanosomiasis-Products under Development by Companies 15

African Trypanosomiasis-Products under Investigation by Universities/Institutes 16

African Trypanosomiasis-Companies Involved in Therapeutics Development 17

Novartis AG 17

Sanofi 18

Scynexis, Inc. 19

African Trypanosomiasis-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 26

Drug Profiles 28

AN-5568-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

DDD-100097-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

fexinidazole-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

GNF-6702-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

melarsoprol hydroxypropylbetadex-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Peptides for Sleeping Sickness-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecules for African Trypanosomiasis-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecules for African Trypanosomiasis and Infectious Diseases-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules for Infectious Diseases-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules for Protozoal Infections-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules for Sleeping Sickness-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

African Trypanosomiasis-Dormant Projects 43

African Trypanosomiasis-Discontinued Products 44

African Trypanosomiasis-Product Development Milestones 45

Featured News & Press Releases 45

Sep 08, 2015: Clinical trial for first oral drug candidate specifically developed for sleeping sickness 45

Mar 12, 2012: Anacor Announces Commencement Of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness 45

Jun 28, 2011: Anacor Pharmaceuticals Partnership Advances New Drug Candidate To Combat Sleeping Sickness 46

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Figures

Number of Products under Development for African Trypanosomiasis, H2 2016 8

Number of Products under Development for African Trypanosomiasis-Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

List of Tables

Number of Products under Development for African Trypanosomiasis, H2 2016 8

Number of Products under Development for African Trypanosomiasis-Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

African Trypanosomiasis-Pipeline by Novartis AG, H2 2016 17

African Trypanosomiasis-Pipeline by Sanofi, H2 2016 18

African Trypanosomiasis-Pipeline by Scynexis, Inc., H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

African Trypanosomiasis-Dormant Projects, H2 2016 43

African Trypanosomiasis-Discontinued Products, H2 2016 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Novartis AG

Sanofi

Scynexis, Inc.

African Trypanosomiasis Therapeutic Products under Development, Key Players in African Trypanosomiasis Therapeutics, African Trypanosomiasis Pipeline Overview, African Trypanosomiasis Pipeline, African Trypanosomiasis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com